Citigroup Upgrades Eisai (OTCMKTS:ESALY) to Buy

Citigroup upgraded shares of Eisai (OTCMKTS:ESALYGet Rating) from a neutral rating to a buy rating in a research report sent to investors on Thursday, The Fly reports.

Separately, Sanford C. Bernstein started coverage on shares of Eisai in a research report on Tuesday. They set an outperform rating for the company.

Eisai Stock Performance

Shares of ESALY opened at $61.51 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.77 and a debt-to-equity ratio of 0.10. The stock has a market cap of $17.64 billion, a P/E ratio of 70.70, a PEG ratio of 2.46 and a beta of 0.31. The company has a 50-day moving average of $61.51 and a two-hundred day moving average of $63.21. Eisai has a 12-month low of $36.88 and a 12-month high of $73.90.

Eisai Company Profile

(Get Rating)

Eisai Co, Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs.

Further Reading

The Fly logo

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with's FREE daily email newsletter.